ClinicalTrials.Veeva

Menu
Z

Zenith Research, Inc. | Beverly Hills, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TAK-279
ESK-001
CC-10004
Apremilast
LY3074828
Deucravacitinib
LY4100511
Zasocitinib
ABP 654
Dice 853

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 10 total trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Active, not recruiting
Plaque Psoriasis
Drug: TAK-279
Drug: Placebo

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque...

Enrolling
Plaque Psoriasis
Drug: Zasocitinib
Drug: Placebo to match zasocitinib

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting
Plaque Psoriasis
Drug: ESK-001
Drug: Placebo

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

Trial sponsors

Takeda logo
A
Amgen logo
D
Lilly logo
O

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems